

PARIS, NOVEMBER 28, 2017

## EURAZEO INVESTS IN DOCTOLIB TO ACCOMPANY ITS INTERNATIONAL EXPANSION

Eurazeo announces the acquisition, through Eurazeo Croissance, of a minority stake in Doctolib, the leading medical online booking platform in Europe, alongside Bpifrance.

Launched in 2013, Doctolib is Europe's leading online booking platform and web services provider for healthcare professionals. The number one e-health service in Europe with 380 employees, Doctolib's sites bring together 30,000 subscriber healthcare professionals, 800 partner healthcare facilities and 12 million visitors each month. Doctolib holds the European e-healthcare sector investment record this year. It has raised total funds of €61 million in 2017, including €26 million in January and an additional €35 million during the latest financing round.

Spearheading the healthcare sector's digital transformation, Doctolib has developed an exceptional business model, which it is rapidly rolling-out in France and Germany. It enjoys considerable growth drivers, thanks to the depth of its target markets in Europe and the sector's extraordinary innovation potential. In the near future, Doctolib will need to accelerate its international expansion, by entering new countries, and extend its product offering to further improve healthcare providers' daily lives.

As a new shareholder, Eurazeo fully supports Doctolib's goals and vision. By providing access to its international business network, corporate capabilities and HR and digital expertise, Eurazeo will contribute to the company's success.

**Yann du Rusquec, Managing Director and head of Eurazeo Croissance, said:** *"We are extremely enthusiastic about our investment in Doctolib. We are delighted to provide our financial capacity and know-how to this company. Doctolib is already part of the daily lives of millions of Europeans and will play a major role in future developments in the healthcare system. The rapid growth of Doctolib, particularly in Germany, was a determining factor in our investment decision. In only one year, the company successfully reproduced in Germany its success in the French market. It was this ability to export its business model that convinced us. Finally, this investment offers us an opportunity to roll-out our flexible approach to supporting high-growth companies."*

**Stanislas Niox-Château, Chairman and co-founder of Doctolib, added:** *"The purpose of this fundraising is straightforward: invest, in order to provide the best possible service to the 30,000 healthcare professionals who place their trust in us every day and the 2,500 new professionals who join them each month. This is the key to putting Doctolib on the road to success. We will also continue to innovate. Our aim: develop new services to facilitate the daily lives of healthcare professionals, digitalize the different stages of patient care and help patients and professionals adapt to changing practices."*

## About Doctolib

- > Created in 2013, Doctolib is the European leader for online booking of medical appointments and internet services for healthcare professionals. For professionals and healthcare centers, Doctolib offers an appointment management SaaS software, as well as services to manage their consultations, communicate with their patients and work with other healthcare professionals. For patients, Doctolib eases their healthcare experience: the search for information and booking of appointments is freely available online, 24/7, and a consultation booklet is accessible online. The company numbers 380 employees in France and Germany. In France, it works with 30,000 healthcare professionals and 800 (private and public) healthcare facilities. In Germany, Doctolib is present in 5 cities (Berlin, Munich, Hamburg, Cologne et Düsseldorf), numbers 1,000 healthcare professionals and large hospital groups using the service and already registered 1.5 million medical appointments.

## About Eurazeo

- > With a diversified portfolio of approximately ~€7 billion in assets under management, of which €1 billion is from third parties, Eurazeo is a leading global investment company with offices in Paris and Luxembourg, New York, Shanghai and Sao Paolo. Its purpose and mission is to identify, accelerate and enhance the transformation potential of the companies in which it invests. The firm covers most private equity segments through its five business divisions – Eurazeo Capital, Eurazeo Croissance, Eurazeo PME, Eurazeo Patrimoine and Eurazeo Brands. Its solid institutional and family shareholder base, robust financial structure free of structural debt, and flexible investment horizon enable Eurazeo to support its companies over the long term. As a global long-term shareholder, the firm offers deep sector expertise, a gateway to global markets, and a stable foothold for transformational growth to the companies it supports. Eurazeo is notably a shareholder in AccorHotels, Asmodee, CIFA, CPK, Desigual, Elis, Europcar, Fintrax, Grape Hospitality, Iberchem, Les Petits Chaperons Rouges, Moncler, Neovia, Novacap, Sommet Education, Trader Interactive, and also SMEs such as Flash Europe, In'Tech Medical and Smile, as well as start-ups such as Farfetch and Vestiaire Collective.
- > Eurazeo is listed on Euronext Paris.
- > ISIN: FR0000121121 - Bloomberg: RF FP - Reuters: EURA.PA

### EURAZEO CONTACTS

CAROLINE COHEN  
HEAD OF INVESTOR RELATIONS  
E-mail : ccohen@eurazeo.com  
Tel: +33 (0)1 44 15 16 76

SANDRA CADIOU  
COMMUNICATION DIRECTOR  
E-mail: scadiou@eurazeo.com  
Tel: +33 (0)1 44 15 80 26

### PRESS CONTACT

HAVAS PARIS  
RENAUD LARGE  
E-mail: renaud.large@havas.com  
Tel: +33 (0)1 58 47 96 30

For more information, please visit the Group's web site: [www.eurazeo.com](http://www.eurazeo.com)

Follow us on [Twitter](#), [Linkedin](#), and [YouTube](#)